Lurasidone Hydrochloride (CAS 367514-88-3)
QUICK LINKS
Lurasidone Hydrochloride is a synthetic compound notable for its affinity and antagonistic activity towards a variety of neurotransmitter receptors, including dopamine D2, serotonin 5-HT2A, and 5-HT7, among others, in the central nervous system. This specific receptor profile allows it to modulate neurotransmitter signaling, affecting the dopaminergic and serotonergic systems, which are in understanding a wide range of neurobiological processes. In research applications, Lurasidone Hydrochloride′s ability to cross the blood-brain barrier and its high receptor selectivity make it useful for investigating the underlying mechanisms of neurotransmission and its impact on neural circuits. Its action at the D2 receptor, for instance, provides insights into dopamine′s role in cognition and behavior, while its effects on serotonin receptors help elucidate the complex interplay between different neurotransmitter systems. By altering neurotransmitter activity, Lurasidone Hydrochloride serves as a critical asset in neuroscientific studies, enabling researchers to dissect the neuropharmacological basis of behavior and neural function, and to explore the molecular underpinnings of neurological conditions.
Lurasidone Hydrochloride (CAS 367514-88-3) References
- Solubility enhancement studies on lurasidone hydrochloride using mixed hydrotropy. | Madan, JR., et al. 2015. Int J Pharm Investig. 5: 114-20. PMID: 25838997
- Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature. | Greenberg, WM. and Citrome, L. 2017. Clin Pharmacokinet. 56: 493-503. PMID: 27722855
- Charge-assisted bond N+H mediates the gelation of amorphous lurasidone hydrochloride during dissolution. | Qian, S., et al. 2017. Int J Pharm. 518: 335-341. PMID: 28043915
- Optimization of Nanostructured Lipid Carriers of Lurasidone Hydrochloride Using Box-Behnken Design for Brain Targeting: In Vitro and In Vivo Studies. | Jazuli, I., et al. 2019. J Pharm Sci. 108: 3082-3090. PMID: 31077685
- Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. | Arango, C., et al. 2020. Eur Child Adolesc Psychiatry. 29: 1195-1205. PMID: 31758359
- Coamorphization combined with complexation enhances dissolution of lurasidone hydrochloride and puerarin with synchronized release. | Wang, S., et al. 2020. Int J Pharm. 588: 119793. PMID: 32827676
- Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan. | Kishi, T., et al. 2020. Neuropsychopharmacol Rep. 40: 417-422. PMID: 32902200
- Stable solid dispersion of lurasidone hydrochloride with augmented physicochemical properties for the treatment of schizophrenia and bipolar disorder. | Pardhi, VP. and Flora, S. 2020. Biopharm Drug Dispos. 41: 334-351. PMID: 33080060
- Influence of the pK a Value of Cinnamic Acid and P-Hydroxycinnamic Acid on the Solubility of a Lurasidone Hydrochloride-Based Coamorphous System. | Hu, Y., et al. 2021. ACS Omega. 6: 3106-3119. PMID: 33553927
- Lurasidone for Adolescents With Complex Mental Disorders: A Case Series. | Mole, TB., et al. 2022. J Pharm Pract. 35: 800-804. PMID: 33757374
- Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression. | DelBello, MP., et al. 2022. J Am Acad Child Adolesc Psychiatry. 61: 243-254. PMID: 34420839
- Inclusion complex of lurasidone hydrochloride with Sulfobutylether-β-cyclodextrin has enhanced oral bioavailability and no food effect. | Wang, J., et al. 2022. Am J Transl Res. 14: 1495-1506. PMID: 35422944
- Lurasidone-induced hyperosmolar hyperglycemic syndrome: A case report. | Hanyu, S., et al. 2022. Neuropsychopharmacol Rep. 42: 377-379. PMID: 35609885
- Effect of sodium lauryl sulfate-mediated gelation on the suppressed dissolution of crystalline lurasidone hydrochloride and a strategy to mitigate the gelation. | Lin, Z., et al. 2022. Int J Pharm. 624: 122035. PMID: 35863597
- Improving Lurasidone Hydrochloride's Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin. | Gamboa-Arancibia, ME., et al. 2023. Pharmaceutics. 15: PMID: 36678861
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Lurasidone Hydrochloride, 5 mg | sc-489135 | 5 mg | $350.00 |